170 related articles for article (PubMed ID: 9129685)
1. New sources and new antitumor drugs in development.
Weiss RB
Semin Oncol; 1997 Apr; 24(2):153-5. PubMed ID: 9129685
[No Abstract] [Full Text] [Related]
2. New drugs target hypoxia response in tumors.
Garber K
J Natl Cancer Inst; 2005 Aug; 97(15):1112-4. PubMed ID: 16077066
[No Abstract] [Full Text] [Related]
3. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
4. Present research trends in cancer chemotherapy.
Eckhardt S
Acta Med Hung; 1994; 50(3-4):133-40. PubMed ID: 8587825
[TBL] [Abstract][Full Text] [Related]
5. The era of cancer discovery.
Cantley LC; Baselga J
Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302
[No Abstract] [Full Text] [Related]
6. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
7. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts.
Nelson B
Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980
[No Abstract] [Full Text] [Related]
8. CC-5013 (Celgene).
Mitsiades CS; Mitsiades N
Curr Opin Investig Drugs; 2004 Jun; 5(6):635-47. PubMed ID: 15242253
[TBL] [Abstract][Full Text] [Related]
9. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.
Wang H; Han H; Mousses S; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):513-20. PubMed ID: 16890805
[TBL] [Abstract][Full Text] [Related]
10. OSI-461 (OSI).
Galmarini CM
Curr Opin Investig Drugs; 2004 Jun; 5(6):648-56. PubMed ID: 15242254
[TBL] [Abstract][Full Text] [Related]
11. New scale assesses benefits of cancer medicines.
Bagcchi S
Lancet Oncol; 2015 Jul; 16(7):e316. PubMed ID: 26051234
[No Abstract] [Full Text] [Related]
12. Learning from exceptional drug responders.
Mullard A
Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
[No Abstract] [Full Text] [Related]
13. BMS-247550 Bristol-Myers Squibb/GBF.
Lin N; Brakora K; Seiden M
Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
[TBL] [Abstract][Full Text] [Related]
14. New checkpoint blockers begin human trials.
Garber K
J Natl Cancer Inst; 2005 Jul; 97(14):1026-8. PubMed ID: 16030295
[No Abstract] [Full Text] [Related]
15. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
[TBL] [Abstract][Full Text] [Related]
16. Slow start to phase 0 as researchers debate value.
Twombly R
J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
[No Abstract] [Full Text] [Related]
17. Researchers may use cancer cell lines to identify target populations prior to clinical trials.
Tuma RS
J Natl Cancer Inst; 2006 Jun; 98(12):810-1. PubMed ID: 16788154
[No Abstract] [Full Text] [Related]
18. MS-209 Schering.
Robert J
Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
[TBL] [Abstract][Full Text] [Related]
19. Comparing antibody and small-molecule therapies for cancer.
Imai K; Takaoka A
Nat Rev Cancer; 2006 Sep; 6(9):714-27. PubMed ID: 16929325
[TBL] [Abstract][Full Text] [Related]
20. AE-941 (AEterna).
Dredge K
Curr Opin Investig Drugs; 2004 Jun; 5(6):668-77. PubMed ID: 15242256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
